Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan

INTRODUCTION: This final analysis of a long-term extension (LTE) study assessed the safety, tolerability, and effectiveness of peficitinib (ASP015K), a pan-Janus kinase inhibitor, in Asian patients with rheumatoid arthritis (RA). METHODS: Patients had previously completed the 12-week phase 2b (RAJ1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Tanaka, Yoshiya, Tanaka, Sakae, Kawakami, Atsushi, Song, Yeong-Wook, Chen, Yi-Hsing, Rokuda, Mitsuhiro, Izutsu, Hiroyuki, Ushijima, Satoshi, Kaneko, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990977/
https://www.ncbi.nlm.nih.gov/pubmed/33656739
http://dx.doi.org/10.1007/s40744-021-00280-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990977/
https://www.ncbi.nlm.nih.gov/pubmed/33656739
http://dx.doi.org/10.1007/s40744-021-00280-5

Ejemplares similares